Weight-loss meds may give people more control over drinking, study shows
Popular obesity and diabetes drugs called GLP-1 medications may have added benefits, with a new study finding they helped heavy drinkers cut alcohol consumption by nearly 70%.
The study, published Friday during the 32nd European Congress on Obesity in Spain, also found these GLP-1 drugs were more effective than a drug called nalmefene, which is approved in Europe explicitly to help people cut back on alcohol.
For the study, researchers followed 262 adults who were prescribed GLP-1 medications like semaglutide or liraglutide to help with weight loss.
The researchers also tracked changes in alcohol use to explore a possible added benefit.
Heavy drinkers -- those consuming 11 or more units of alcohol per week, roughly equal to six or more standard drinks like beers or glasses of wine -- saw the biggest drops in consumption. Notably, no participants reported drinking more after starting the medication. And it seemed to work equally well for men and women.
Patients also lost about 17 pounds on average over four months. People who drank less tended to lose a little more weight, the researchers noted, possibly because they were cutting back on alcohol's empty calories.
"The significance of this has to be taken into context of what's available to treat alcohol use disorder," Dr. Maurice O'Farrell, lead author of the study and founder of the Medication Weight Loss Clinic in Dublin, Ireland, told ABC News. "The real advantage that this medication has is compliance, and what this medication does is it gives people a degree of control, it gives the concrete guardrails, and that is something that is completely unique."
Women turn to weight loss drugs in menopause: What to know about the benefits and risks
Scientists have been studying other possible health benefits of GLP-1s besides diabetes management and weight loss for this class of medication, which includes drugs like Ozempic and Wegovy, in the wake of their booming popularity.
Prior studies and anecdotal reports from patients have hinted that these medications may help cut cravings for alcohol and other addictive substances. One possible explanation is that they act on parts of the brain that control reward and satisfaction.
According to the study, GLP-1 drugs may affect brain chemicals tied to pleasure and fullness, though more research is needed to fully understand the exact mechanism.
"They attenuate dopamine release in reward pathways, and these pathways are common to food satisfaction but also to the pleasure people get from alcohol," O'Farrell said. "They drink more slowly and also the gastric emptying is slowed -- that means the absorption of alcohol is slower, so it is less pleasurable."
Because this study took place in a real-world clinical setting -- not a controlled lab -- it may better reflect how people actually drink alcohol in everyday life.
Woman says Ozempic helped her stop drinking: Here's what the research says about how it may work
But the study did have a few limitations. There was no control group for comparison and researchers relied on people to report their own drinking habits, which they don't always remember accurately. About a third of the participants didn't complete the study, which makes the results less certain.
If these results are confirmed in larger studies, O'Farrell said he thinks they could offer a new way to help people cut back on alcohol, especially those who haven't had success with current treatments.
Dr. Keerthana Pakanati is a Cardiovascular Disease Fellow at Virginia Mason Franciscan Health and a member of the ABC News Medical Unit.
Weight-loss meds may give people more control over drinking, study shows originally appeared on goodmorningamerica.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
33 minutes ago
- Medscape
BMI & Nutrition Support Predict Weight Loss in Liver Disease
In patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), higher BMI, nutritionist support, and liver stiffness measurement ≥ 10 kPa were significant predictors of at least 7% weight reduction. METHODOLOGY: Researchers conducted a retrospective study to identify clinical factors that predict successful and sustained weight loss in 897 patients with MASLD (mean age, 61.6 years; 57.1% men; mean BMI, 30.3). They were referred between January 2019 and December 2021, with follow-up occurring between 18 and 24 months at four Italian tertiary centres. The diagnosis of MASLD was confirmed if patients had hepatic steatosis on ultrasound and at least one cardiometabolic risk factor, such as a BMI ≥ 25 or high waist circumference, fasting glucose levels ≥ 100 mg/dL or type 2 diabetes, blood pressure ≥ 130/85 mm Hg, triglyceride levels ≥ 150 mg/dL, or low levels of high-density lipoprotein cholesterol. Baseline and follow‐up data, including demographic, anthropometric, clinical, and biochemical parameters, as well as liver stiffness measurements, were collected from medical records. Details on lifestyle interventions such as Mediterranean diet recommendations, physical activity, and support from a nutritionist were also noted. TAKEAWAY: Over a median duration of 21 months, 18.3% of patients achieved at least 7% weight loss, with 8.5% losing 7%-10% and 9.8% losing more than 10% of their baseline weight. Higher baseline BMI was associated with increased odds of weight loss, with BMI 30-34.9 (adjusted odds ratio [aOR], 1.95; 95% CI, 1.30-2.95) and BMI ≥ 35 (aOR, 2.08; 95% CI, 1.21-3.57) associated with at least 7% weight loss. Nutritionist support (aOR, 2.04; 95% CI, 1.12-3.71), liver stiffness measurement ≥ 10 kPa (aOR, 1.70; 95% CI, 1.07-2.70), and bilirubin levels ≥ 1.2 mg/dL (aOR, 2.12; 95% CI, 1.29-3.51) were independent predictors of achieving at least 7% weight loss. The use of GLP-1 agonists was significantly associated with an increased likelihood of losing at least 7% weight (aOR, 1.85; 95% CI, 1.19-3.80). IN PRACTICE: "Our findings underscore the importance of a comprehensive approach to MASLD management, encompassing medical, nutritional and lifestyle interventions," the authors of the study wrote. "Lifestyle intervention remains crucial for all patients, but for those without predictive factors, close follow-up and early consideration of additional treatments are warranted to maximize therapeutic benefit," they added. SOURCE: This study was led by Nicola Pugliese, Humanitas University, Milan, Italy. It was published online on June 04, 2025, in United European Gastroenterology Journal . LIMITATIONS: This study was retrospective in nature with varying observation periods among the patients. A standardised intervention protocol was lacking across centres, potentially leading to varying management. The absence of systematic data collection from intermediate visits and self-reported data also presented a limitation. DISCLOSURES: This study was supported by funding from the Italian Ministry for Education, University and Research and other projects to an author. The authors reported having no conflicts of interest.
Medscape
33 minutes ago
- Medscape
Add-On Simvastatin Shows No Benefit in Depression
In a trial of patients with major depressive disorder (MDD) and obesity, adding simvastatin to escitalopram treatment led to no significant reduction in depressive symptoms compared with placebo; however, the combination effectively reduced levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). METHODOLOGY: This confirmatory, double-blind, placebo-controlled trial included 160 adults (mean age, 39 years; 79% women) with MDD and comorbid obesity from nine tertiary care centres in Germany. Participants were randomly assigned to receive either simvastatin (40 mg/d; n = 81) or placebo (n = 79) as add-on to escitalopram (10 mg for the first 2 weeks, then increased to 20 mg until the end of the study) for 12 weeks. The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 12. The key secondary outcome was the change in self-reported Beck Depression Inventory II (BDI-II) scores. TAKEAWAY: Compared with the use of add-on placebo, the use of add-on simvastatin led to no significant change in MADRS scores ( P = .71) and BDI-II scores ( P = .70). = .71) and BDI-II scores ( = .70). Moreover, compared with the use of add-on placebo, the use of add-on simvastatin led to a significant reduction in levels of LDL cholesterol ( P < .001), total cholesterol ( P < .001), and CRP ( P = .003). < .001), total cholesterol ( < .001), and CRP ( = .003). Add-on simvastatin did not affect any mental health-related secondary endpoint, despite improving the cardiovascular risk profile. Four severe adverse events were reported, with no significant differences observed between the groups. IN PRACTICE: "Even though simvastatin did not exert additional antidepressive effects in our study, it had the expected and well-known effects on lipids and inflammatory activity. Given that both MDD and obesity are associated with increased cardiovascular risk and higher mortality, statins should be prescribed in this comorbid group of patients following the guidelines for statin use in primary prevention," the authors wrote. SOURCE: This study was led by Christian Otte, MD, Charité — Universitätsmedizin Berlin, Berlin, Germany. It was published online on June 04 in JAMA Psychiatry . LIMITATIONS: This study was conducted in tertiary care centres in a high-income country, with patients showing moderate symptom severity and a high response rate, which limited its generalisability. Additionally, participants with an established indication for statin treatment and those with a history of suicide attempt were not included. DISCLOSURES: This study was supported by a grant from the German Ministry of Education and Research and sponsored by Charité — Universitätsmedizin Berlin. Several authors reported receiving grants and personal fees from various sources, outside the submitted work. Details are provided in the original article.
Vogue
42 minutes ago
- Vogue
2 Eggs for Breakfast for 2 Weeks: All The Benefits I've Experienced
One morning over breakfast, naturopath Juliette Andreau surprises me with some news: Eggs are one of the only complete foods out there. 'They contain many of the nutrients we need,' she says, making me regret ordering a giant, flaky croissant. 'An egg has high-quality protein, fats, vitamins A, D, E, and B 12 , choline, and minerals like selenium or zinc.' This incredible nutritional profile is why she recommends eating eggs every morning at breakfast: 'If you digest them well and have no known allergies or intolerances, there's no need to worry about eating them every day,' she explains. For a long time, eggs were demonized because of cholesterol, but today we know that dietary cholesterol is not the 'big bad' thing that we thought it was, especially when you're consuming it as part of a balanced overall diet. That said, as with everything, it's quality that makes the difference. 'Organic, free-range eggs (even better if from a small producer) are a completely different story from industrial eggs,' says Andreau. As for the number of eggs to eat each day, she suggests two (or even three if it's the only source of protein in the meal). The result? 'It's easier to build muscle, you'll have fewer morning cravings, feel full for longer, and a positive effect on mood.' According to Andreau, the benefits can be seen very quickly—even more so if the eggs are replacing a carb-y option, say a daily croissant habit, ahem—though you should fully implement a habit for at least two weeks to understand the full results. I did just that—read on for my experience. Eating eggs every day: what are the health benefits? Greater mental clarity. Choline is an essential nutrient that helps with the nervous system and regulates mood. One egg has about 30% of your daily choline needs. Better hormonal balance. Cholesterol is vital for hormone production. Better vision. 'Lutein and zeaxanthin are both found in eggs,' says Andreau. 'These nutrients help filter eyes filter out blue light, protecting them from all the time we spend staring at screens.' Stronger, shinier, silkier hair. Both sulfur and biotin (a type of vitamin B) can be found in eggs. 'Both of these nutrients, along with amino acids such as methionine, which support healthy skin and nails and produce keratin.' Preferred cooking methods 'Gentle cooking is key," says Andreau. 'Ideally, eggs should be soft-boiled or poached. When the yolk remains slightly runny, all the vitamins and minerals that are sensitive to heat remain intact. By cooking them too intensely, in the form of hard-boiled eggs or omelettes, we lose some of these precious nutrients, and the fats can oxidize.'
